Predicted to enable neuropeptide binding activity; pancreatic polypeptide receptor activity; and peptide YY receptor activity. Involved in several processes, including positive regulation of vasoconstriction; regulation of presynaptic cytosolic calcium ion concentration; and regulation of secretion by cell. Located in several cellular components, including axon; cytosol; and synaptic vesicle. Is active in glutamatergic synapse; neuronal dense core vesicle; and presynaptic membrane. Used to study anxiety disorder; childhood absence epilepsy; hypertension; and mental depression. Biomarker of obesity and visual epilepsy. Orthologous to human NPY1R (neuropeptide Y receptor Y1); INTERACTS WITH 17beta-estradiol; 1D-myo-inositol 1,4,5-trisphosphate; 2,3,7,8-tetrachlorodibenzodioxine.
[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of NPY1R mRNA, Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NPY1R mRNA]
[2-amino-3-chloro-1, 4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of NPY1R mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPY1R mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPY1R mRNA
[bisphenol A co-treated with Estradiol] results in increased expression of NPY1R mRNA, [bisphenol A co-treated with Genistein] results in increased methylation of NPY1R gene
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPY1R mRNA
[2-amino-3-chloro-1, 4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of NPY1R mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY1R mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY1R mRNA
[2-amino-3-chloro-1, 4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of NPY1R mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPY1R mRNA
[2-amino-3-chloro-1, 4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of NPY1R mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY1R mRNA
[2-amino-3-chloro-1, 4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of NPY1R mRNA
The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression.
Expression of neuropeptide Y and its receptors Y1 and Y2 in the rat heart and its supplying autonomic and spinal sensory ganglia in experimentally induced diabetes.
Ultrastructural localization of neuropeptide Y Y1 receptors in the rat medial nucleus tractus solitarius: relationships with neuropeptide Y or catecholamine neurons.
Differential regulation of mRNAs for neuropeptide Y and its receptor subtypes in widespread areas of the rat limbic system during kindling epileptogenesis.
Modulation of intracellular calcium changes and glutamate release by neuropeptide Y1 and Y2 receptors in the rat hippocampus: differential effects in CA1, CA3 and dentate gyrus.
Ultrastructural Characterization of Corticotropin-Releasing Factor and Neuropeptide Y in the Rat Locus Coeruleus: Anatomical Evidence for Putative Interactions.
Activation of neuropeptide Y Y1 receptors inhibits glutamate release through reduction of voltage-dependent Ca2+ entry in the rat cerebral cortex nerve terminals: suppression of this inhibitory effect by the protein kinase C-dependent facilitatory pathway.
